These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6471944)

  • 1. [Early morning dystonia: a complication of levodopa therapy in Parkinson disease. Presentation of 4 cases].
    Molina Arjona JA; Arnal García C; Calandre Hoenigsfeld L; Bermejo Pareja F
    Med Clin (Barc); 1984 Jun; 83(2):47-9. PubMed ID: 6471944
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacology of foot dystonia in parkinsonism.
    Poewe WH; Lees AJ
    Clin Neuropharmacol; 1987; 10(1):47-56. PubMed ID: 3545460
    [No Abstract]   [Full Text] [Related]  

  • 3. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile.
    McHale DM; Sage JI; Sonsalla PK; Vitagliano D
    Clin Neuropharmacol; 1990 Apr; 13(2):164-70. PubMed ID: 2328507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin.
    Pacchetti C; Albani G; Martignoni E; Godi L; Alfonsi E; Nappi G
    Mov Disord; 1995 May; 10(3):333-6. PubMed ID: 7651452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
    Klawans HL; Paleologos N
    Clin Neuropharmacol; 1986; 9(3):298-302. PubMed ID: 3719575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology.
    Poewe W; Lees AJ; Steiger D; Stern GM
    Adv Neurol; 1987; 45():357-60. PubMed ID: 3825711
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinsonism following dystonia in three patients.
    Katchen M; Duvoisin RC
    Mov Disord; 1986; 1(2):151-7. PubMed ID: 3504239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forms of dystonia in patients with Parkinson's disease.
    Kidron D; Melamed E
    Neurology; 1987 Jun; 37(6):1009-11. PubMed ID: 3587617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
    Nygaard TG
    Adv Neurol; 1993; 60():577-85. PubMed ID: 8420194
    [No Abstract]   [Full Text] [Related]  

  • 10. A family with hereditary juvenile dystonia-parkinsonism.
    Ishikawa A; Miyatake T
    Mov Disord; 1995 Jul; 10(4):482-8. PubMed ID: 7565830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].
    Miwa H; Mizuno Y
    No To Shinkei; 1996 Feb; 48(2):149-54. PubMed ID: 8865694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease.
    Ho B; Prakash R; Morgan JC; Sethi KD
    Nat Clin Pract Neurol; 2007 Sep; 3(9):526-30. PubMed ID: 17805247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA-responsive dystonia.
    Furukawa Y; Mizuno Y; Narabayashi H
    Adv Neurol; 1996; 69():327-37. PubMed ID: 8615147
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF biopterin levels and clinical features of patients with juvenile parkinsonism.
    Furukawa Y; Nishi K; Kondo T; Mizuno Y; Narabayashi H
    Adv Neurol; 1993; 60():562-7. PubMed ID: 8420192
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopa-responsive dystonia: a widening spectrum.
    Gordon N
    Dev Med Child Neurol; 1996 Jun; 38(6):554-9. PubMed ID: 8647336
    [No Abstract]   [Full Text] [Related]  

  • 18. Pisa syndrome as a motor complication of Parkinson's disease.
    Kim JS; Park JW; Chung SW; Kim YI; Kim HT; Lee KS
    Parkinsonism Relat Disord; 2007 Mar; 13(2):126-8. PubMed ID: 16731022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
    Olsson JE; Duchek M; Ekberg R; Fehling C; Johansson F; Johnels B; Lindvall B; Nordin G; Sidén A; Steg G
    Lakartidningen; 1993 Apr; 90(16):1545-8. PubMed ID: 8483351
    [No Abstract]   [Full Text] [Related]  

  • 20. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.